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ABSTRACT Ventilator-associated bacterial pneumonia (VABP) is a difﬁcult therapeutic
problem. Considerable controversy exists regarding the optimal chemotherapy for this
entity. The recent guidelines of the Infectious Diseases Society of America and the Amer-
ican Thoracic Society recommend a 7-day therapeutic course for VABP based on the bal-
ance of no negative impact on all-cause mortality, less resistance emergence, and fewer
antibiotic treatment days, counterbalanced with a higher relapse rate for patients whose
pathogen is a nonfermenter. The bacterial burden causing an infection has a substantial
impact on treatment outcome and resistance selection. We describe the baseline bron-
choalveolar lavage (BAL) ﬂuid burden of organisms in suspected VABP patients screened
for inclusion in a clinical trial. We measured the urea concentrations in plasma and BAL
ﬂuid to provide an index of the dilution of the bacterial and drug concentrations in the
lung epithelial lining ﬂuid introduced by the BAL procedure. We were then able to cal-
culate the true bacterial burden as the diluted colony count times the dilution factor.
The median dilution factor was 28.7, with the interquartile range (IQR) being 11.9 to
53.2. Median dilution factor-corrected colony counts were 6.18 log10(CFU/ml) [IQR, 5.43
to 6.46 log10(CFU/ml)]. In a subset of patients, repeat BAL on day 5 showed a good sta-
bility of the dilution factor. We previously showed that large bacterial burdens reduce or
stop bacterial killing by granulocytes. (This study has been registered at ClinicalTrials.gov
under registration no. NCT01570192.)
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The practice guidelines for hospital-associated bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP) recently released by the Infectious Diseases
Society of America and the American Thoracic Society (1) recommend a 7-day duration
of antibiotic therapy, irrespective of the causative pathogen(s). This recommendation is
primarily based on the prior work of Chastre et al. (2), who found no signiﬁcant
difference in mortality between 8 versus 15 days of therapy (all-cause mortality, 18.8%
versus 17.2%; P  not signiﬁcant) in a randomized, double-blind (until day 8) trial
comparing 8 versus 15 days of therapy for bronchoalveolar lavage (BAL)-proven VABP.
There was a statistically signiﬁcant increase in the rate of relapse (40.6% versus 25.4%;
90% conﬁdence interval for between-group risk difference, 3.9 to 26.6) in patients in the
group infected with either Pseudomonas aeruginosa or Acinetobacter spp. (nonfer-
menter bacteria) receiving therapy for 8 days. However, there was also a signiﬁcantly
lower rate of resistance emergence (42.1% versus 62.3%; P  0.04) and there was a
higher number of antibiotic-free days (18.4  8.0 versus 15.3  8.4 days; P  0.01) in
the group receiving therapy for 8 days.
Given the high rate of relapse in both therapy duration groups, it is imperative to
critically examine the indices of therapy intensity that may have a salutary impact on
these relapse rates. The goal of antibiotic therapy is to drive the organism burden to
eradication or reduce it to a point where the patient’s immune system can clear the
remaining organisms. We have shown previously in a murine pneumonia model that
the capacity of granulocytes to clear microbes from an infection site can be saturated
or overwhelmed when the bacterial burden is large (3). We have also demonstrated (4)
with the aminoglycoside plazomicin that early aggressive therapy sufﬁcient to substan-
tially reduce the bacterial burden to below 5 log10(CFU/g) allows the granulocytes to
regain bacterial killing function, resulting in a 1.0- to 1.5-log10(CFU/g) additional decline
in the bacterial burden in the absence of further antimicrobial therapy. Having aggres-
sive or immediately adequate antimicrobial therapy may then play a critical role in
improving the outcome (5), decreasing rates of relapse, and shortening the time on
mechanical ventilation.
One of the pieces of information, other than microbiology laboratory pathogen
susceptibility data, that may help deﬁne adequate therapy is the concentration of the
antibiotic(s) chosen for initial therapy at the primary infection site (here, at the primary
infection site in patients with VABP). We have recently examined patients with sus-
pected VABP who then had a BAL as an admission criterion for the study. In this set of
patients, besides quantitating the number of pathogens in BAL ﬂuid, we also deter-
mined the urea concentration in BAL ﬂuid and plasma. This allowed us to calculate the
dilution factor introduced by the BAL. This information allows the real baseline bacterial
burden to be calculated. It also provides important information regarding the amount
of bacterial cell kill required for granulocytes to regain their bacterial killing function.
RESULTS
BAL ﬂuid samples were available for 43 patients who had a BAL for study entry
qualiﬁcation on day 1, of whom 33 had an organism recovered at10,000 colonies/ml.
The recovered organisms are displayed in Table 1. As part of the protocol, enrolled and
treated patients received a second BAL for evaluation of drug penetration into the
epithelial lining ﬂuid (ELF) whenever possible. BAL ﬂuid samples were available for 20
patients to assess the dilution factor on day 5 versus that on day 1.
The dilution factor for the number of recovered organisms, along with the corrected
(by the dilution factor) colony counts, is shown in Table 2. The day 5 mean dilution
factor (n 20) was 115, the median dilution factor was 47.6, the standard deviation was
185, and the 25th percentile and 75th percentile values were 17.2 and 123, respectively.
From day 1, the same 20 patients had a mean dilution factor of 116, a median dilution
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factor of 29.4, a standard deviation dilution factor of 189, and 25th and 75th percentile
dilution factors of 18.3 and 103, respectively.
The correlation between the day 1 and day 5 dilution factors is shown in Fig. 1. The
regression line was log(day 5 dilution factor)  0.851  log(day 1 dilution factor) 
0.299 (r2  0.714; P  0.000003). This and the data in Table 2 demonstrate that the
dilution factor range is broad but relatively stable over the ﬁrst 5 days of therapy.
DISCUSSION
The treatment of VABP remains a challenge. Ultimately, patient survival is the single
most important variable, but VABP is associated with several other outcomes that are
also important. As noted above (2), there is a very high rate of resistance emergence
during therapy that is altered by the duration of antimicrobial therapy, with the rate of
resistance emergence ranging from 42.1% with 8 days of antibiotic therapy to 62.3%
with 15 days of treatment. The rate of relapse is also substantial, particularly for those
infected with Gram-negative bacilli.
Understanding the bacterial burden at the baseline may be important in further
limiting resistance emergence and in minimizing relapses. The likelihood of resistance
emergence is altered by the presence of primary resistant mutants in the bacterial
population. It is also determined by the drug(s) chosen for therapy; by the frequency
of mutation of the pathogen to resistance to the antimicrobial agent(s), which is also
TABLE 1 Organisms and bacterial burden from patients undergoing BAL
Organism
No. of
patients
No. of patients from whom the organism
was recovered at >10,000 colonies/ml
(diluted)/total no. tested
Total 43 33/43
Gram-positive bacteria
Staphylococcus aureus 6/7
Methicillin sensitive 4
Methicillin resistant 3
Streptococcus pneumoniae 1 1/1
Other streptococci 1 0/1
Gram-negative bacteria
Pseudomonas aeruginosa 17 13/17
Enterobacter spp. 3/4
Enterobacter cloacae 3
Enterobacter aerogenes 1
Stenotrophomonas maltophilia 3 2/3
Klebsiella pneumoniae 2 2/2
Serratia marcescens 2 2/2
Escherichia coli 2 0/2
Hafnia alvei 2 2/2
Proteus vulgaris 1 1/1
Candida albicans 1 1/1
TABLE 2 Dilution factor introduced by BAL and the dilution factor-corrected baseline
bacterial burden in patients with ventilator-associated pneumonia on day 1
Parameter
Dilution factor
(n  33)
Dilution factor-corrected no. of
log10(CFU/ml) (n  17)a
Mean 85.2 5.88
Median 28.7 6.18
SD 153 0.68
25th percentile 11.9 5.43
75th percentile 53.2 6.46
aNumber of patients whose baseline bacterial burden (undiluted) of Gram-negative pathogens was 104 and
for whom a dilution factor was also calculated on day 1.
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inﬂuenced, for example, by whether the organism is a hypermutator; and ﬁnally, by the
size of the total bacterial burden (6, 7).
Quantifying the size of the bacterial burden allows the physician to make rational
decisions regarding the ultimate choice of therapy after the empirical phase. Table
2 demonstrates that when the bacterial burden in BAL ﬂuid determined by quan-
titative culture was 104 CFU/ml, accounting for the dilution factor disclosed that
50% of patients had an actual baseline bacterial burden in ELF of 106.2 CFU/ml.
When placed in the proper clinical perspective, our data demonstrate that a high
percentage of patients with VABP have a baseline bacterial burden that exceeds the
inverse of the frequency of mutation to resistance. The mutational frequency is
often in the range of 1/107 to 1/108 (8). These patients both have a high concen-
tration of organisms in the sampled area and, in addition, often have a substantial
(multilobar) involvement of their pneumonic process. As the amount of lung
involvement increases, the total bacterial burden increases and the number of less
susceptible bacteria in the population at the baseline increases. These patients are
at a particularly high risk for the emergence of resistance to an antibiotic admin-
istered as monotherapy and may beneﬁt most from a combination chemothera-
peutic approach.
In addition, in order to extubate patients quickly (minimize the number of ventilator
days), have them leave the intensive care unit (ICU) (minimize the number of ICU days),
and lower the rate of relapse, particularly in the treatment of VABP caused by Gram-
negative nonfermenter bacteria, we need to maximize the rate and extent of killing of
the infecting pathogen. To accomplish this goal, optimization of the host defense is
also necessary. Clearly, granulocytes are a major line of defense in this circumstance. It
has previously been demonstrated (3, 4) that high concentrations of bacteria can
saturate granulocytes to overwhelm their antimicrobial functions and suppress their
killing of infecting pathogens. Adequate antimicrobial chemotherapy has demon-
strated (Fig. 2) an ability to reduce the saturation of granulocyte antimicrobial functions
and allow the granulocytes to add 1 log10(CFU/g) kill over 24 h in the absence of
further drug therapy (4). In the example shown in Fig. 2, the investigational aminogly-
coside plazomicin was administered to mice with P. aeruginosa pneumonia using a
dosing algorithm which humanized the pharmacokinetic proﬁle of the drug in the
plasma of the mice for the ﬁrst 24 h of the experiment, at which time the ﬁrst cohorts
of mice were sacriﬁced for quantitative culture of lung tissue specimens. Other cohorts
FIG 1 Regression between day 1 (D1) and day 5 (D5) dilution factors caused by BAL (n  20). The lower
and upper 95% conﬁdence interval about the regression line and the 95% prediction interval (which
refers to the observations) are indicated. The regression line was log(day 5 dilution factor)  0.851 
log(day 1 dilution factor)  0.299 (r2  0.714; P  0.000003).
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of mice were observed for an additional 24 h without further antibiotic therapy before
quantitative cultures of their lung tissue specimens were assessed. With this dosing
algorithm, the residual drug concentration was approximately 1/4 MIC (MIC  2
mg/liter for plazomicin) for the infecting pathogen (Pseudomonas aeruginosa) at the
time with no further antimicrobial therapy. The two blue horizontal lines in Fig. 2
show the maximal kill obtained at 24 h of therapy (hour 26 of the experiment) and
24 h later (hour 50 of the experiment). This difference is due to the return of
granulocyte function and is maximal when the bacterial burden is reduced to less
than 5 log10(CFU/g).
Given that 25% of our patients had dilution factor-corrected bacterial burdens that
exceeded 6.46 log10(CFU/ml) prior to initiation of antimicrobial therapy, the initial
therapeutic choice should generate a minimum kill of 1.5 to 2.0 log10(CFU/ml). Maxi-
mization of antimicrobial therapy is most critical in patients with the largest actual
bacterial burden to maximize the probability of attaining this magnitude of initial
pathogen kill. Obtaining this goal has the possibility of helping suppress the emer-
gence of resistance, lead to earlier extubation, and (it is hoped) diminish the possibility
of a relapse. Determination of the true bacterial burden may be a helpful tool to
understand the results of disappointing clinical trials in patients with VABP and design
better interventions. Measurement of BAL ﬂuid and serum urea concentration should
be considered for future studies of VABP. The clinical characteristics of the patients or
the technical aspects of BAL ﬂuid samples with altered dilution factors also need further
exploration.
MATERIALS AND METHODS
A brief description of the study is found in the supplemental material. The trial identiﬁers are
ClinicalTrials.gov identiﬁer NCT01570192, DMID protocol number 10-0060, and EudraCT registration
number 2012-003483-46. For this study, we analyzed the BAL ﬂuid sample that qualiﬁed patients for
study inclusion and a repeat BAL ﬂuid sample that was obtained on approximately day 5 for drug
concentration measurement. (Each participating institution had the protocol evaluated and approved by
their local institutional review board.)
FIG 2 Demonstration of bacterial clearance attributable to granulocytes after adequate chemotherapy results in
the decline of the bacterial burden to a point that returns the antimicrobial capability of the granulocytes. Blue
lines, the bacterial burdens at hours 26 and 50. The difference between the lines is due to bacterial cell kill by
granulocytes alone. Error bars represent standard deviations. Modiﬁed from the Journal of Infectious Diseases (4)
with permission of the publisher.
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Bronchoalveolar lavage. A ﬁberoptic bronchoscope (FOB) was positioned so that the tip of the
scope could be wedged in a distal airway. The sampling area was selected on the basis of the location
of the radiographic inﬁltrate. In patients with diffuse pulmonary inﬁltrates or minimal new changes in a
previously abnormal chest radiograph, sampling was directed to the area where endobronchial abnor-
malities were maximal. An initial aliquot of 20 to 30 ml was instilled, aspirated, and discarded. Serial 50-ml
aliquots of sterile saline were administered through the suction channel of the FOB using a sterile
syringe. The same syringe was used to aspirate back each BAL ﬂuid aliquot. The pooled second and third
aliquot samples constituted the BAL ﬂuid sample (9).
Quantitative culture methodology. Bacterial culture of the pooled BAL ﬂuid sample was performed
according to the routine clinical protocol. A cytocentrifuged sample of BAL ﬂuid was Gram stained.
Aerobic cultures were performed by serial dilution or calibrated loop techniques. Bacteria present at a
concentration of 1  103 CFU/ml BAL ﬂuid specimen or higher were identiﬁed.
Urea instrumentation summary. Determination of the urea concentration was performed using
liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a Prominence high-performance
liquid chromatography (HPLC) column (Shimadzu) and an API5000 triple-quadrupole mass spectrometer
(AB Sciex). Separation was achieved using a Gemini NX C18 150- by 4.6-mm (particle size, 4-m) HPLC
column (Phenomenex) at 40°C with a run time of 5 min. The mobile phases consisted of water (mobile
phase A) and methanol (mobile phase B), which were injected at a ﬂow rate of 0.750 ml/min in the
isocratic mode at 20% mobile phase B with an injection volume of 10 l.
The mass spectrometer was operated in the positive-ion mode using a turbo ion spray (TIS) probe
interface. A multiple-reaction-monitoring (MRM) m/z 60.1/44.0 was used for urea, and an MRM m/z
62.124/45.0 was used for the labeled internal standard, [15N2]urea. The parameters for the API5000 mass
spectrometer (arbitrary units) were as follows: CAD (collision cell gas setting), 6; CUR (curtain plate gas
setting), 30; GS1 (gas 1; nebulizer gas setting), 60; GS2 (gas 2; auxiliary gas setting), 60; IS (IonSpray
voltage), 5,500; TEM (temperature of heater gas), 650°C; MRM, m/z 60.1/44.0; DP (declustering potential),
60; CE (collision cell energy), 28; CXP (collision cell exit potential), 15; dwell time, 200 ms; MRM, m/z
62.124/45.0; DP, 101; CE, 27; CXP, 10; dwell time, 200 ms. Calculated concentrations were performed
using Analyst software v1.6.2 (ABSciex, Redwood City, CA).
Analysis of plasma urea concentrations in patient samples. A plasma sample for measurement of
the urea concentration was collected from each patient at about the same time that the BAL was
conducted. This sample was centrifuged and stored at 80°C until it was assayed for urea
concentrations. Prior to analysis, all samples were thawed at room temperature. Once they were
thawed, the samples were vortexed for 1 min, followed by centrifugation for 10 min at 0.835  g.
Twenty-ﬁve microliters of each sample was added to a 1.7-ml microcentrifuge tube, followed by the
addition of 10 l of the [15N2]urea internal standard (25 g/ml in water) and 100 l of LC-MS-grade
water. The tubes were then capped, vortexed well for 1 min, and centrifuged at 16,168  g for 10
min. A 25-l aliquot of the sample supernatant was then transferred to a 96-well plate, followed by
the addition of 500 l of LC-MS-grade water. The plate was then covered and vortexed gently for
1 min, prior to loading of a sample onto the LC-MS/MS system for analysis using a 10-l injection
volume.
Linearity of the urea concentration in plasma. The linearity of the urea concentration in plasma
over a range of 5.00 to 500 g/ml was demonstrated for each calibration curve over 3 separate runs, with
a correlation coefﬁcient (R) of0.9994 and a linear regression coefﬁcient (R2) of0.9987. The within-run
accuracy as well as the between-run accuracy for each calibration curve was within10% of the nominal
concentrations, and the respective coefﬁcients of variation of the mean values were 0.1%. The
calibration curve precision range was 0.7% to 4.3% within runs and 0.1% to 5.7% between runs. The
within-run and between-run accuracies of quality control (QC) samples were within 10% of the
nominal concentrations, and the coefﬁcients of variation were 0.7% of the mean values. For the QC
samples, the within-run precision ranged from 0.4% to 8.2% and the between-run precision ranged
from 0.2% to 9.2%.
BAL ﬂuid urea concentration analysis. The method used to analyze the urea concentration in BAL
ﬂuid was the same as that described above for plasma. The calibration curves for the urea concentration in
BAL ﬂuid were linear over a range of 0.500 to 100 g/ml, with a correlation coefﬁcient (R) of 0.9989 and a
linear regression coefﬁcient (R2) of0.9978. The accuracy for each calibration curve was within15% of the
nominal concentrations, and the respective coefﬁcients of variation of the mean values were 15%.
Calibration curve precision ranged from 0.2% to 9.7%. For the QC samples, accuracy was within 10%
of the nominal concentrations, and the respective coefﬁcients of variation of the mean values were5%.
The precision for the QC samples ranged from 1.2% to 5.3%.
The dilution factor was calculated as described by Rennard et al. (10).
Statistics. The dilution factor was calculated as the estimate of the urea concentration in plasma
divided by the estimate urea concentration measured in BAL ﬂuid. All statistical evaluations were
performed with the SYSTAT program for Windows (v13.0).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.01323-17.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.1 MB.
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